Biweekly gemcitabine plus vinorelbine in first-line metastatic breast cancer: efficacy and correlation with HER2 extracellular domain
- 1 December 2006
- journal article
- research article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 8 (12) , 896-902
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): Phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factorOncology Reports, 2005
- Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rateAnnals of Oncology, 2005
- Serum HER-2/neu as a prediction and monitoring parameter in a phase II study with weekly paclitaxel in metastatic breast cancer.2004
- Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer.2004
- Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma.2004
- 553 Alternate administration sequences of gemcitabine/vinorelbine in advanced solid tumor: a pharmacokinetic studyEuropean Journal of Cancer Supplements, 2003
- Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: a phase II studyCancer Chemotherapy and Pharmacology, 2003
- Taxane/Anthracycline Combinations: Setting a New Standard in Breast Cancer?The Oncologist, 2001
- A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinomaCancer, 1999
- Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxolOncogene, 1998